Serum levels of serum interleukin 2 receptor α or β-2-microglobulin from the small-tumor-burden therapeutic study2-154
| . | Days after therapy . | ||||||
|---|---|---|---|---|---|---|---|
| − 3 . | 11 . | 28 . | 42 . | ||||
| sIL-2Rα (× 103) . | sIL-2Rα (× 103) . | β2M . | sIL-2Rα (× 103) . | β2M . | sIL-2Rα (× 103) . | β2M . | |
| Control | 4.05 ± 2.98 | 35.89 ± 17.69 | 1.07 ± 0.65 | 526.3 ± 446.4 | 7.74 ± 3.33 | NA | NA |
| HAT | 4.04 ± 2.92 | 4.76 ± 8.78 | 0.11 ± 0.27 | 4.8 ± 6.2** | 0.63 ± 0.87*** | 100.9 ± 111.8 | 2.51 ± 2.54 |
| PRIT | 4.03 ± 3.46 | 1.89 ± 3.38 | 0.03 ± 0.08 | 9.8 ± 16.6** | 0.44 ± 0.84*** | 44.4 ± 62.6 | 1.33 ± 2.25 |
| PRIT (ns) | 4.02 ± 3.16 | 17.14 ± 9.85 | 0.60 ± 0.38 | 259.0 ± 258.9 | 4.47 ± 2.87* | 359.6 ± 123.5 | 8.43 ± 2.27 |
| . | Days after therapy . | ||||||
|---|---|---|---|---|---|---|---|
| − 3 . | 11 . | 28 . | 42 . | ||||
| sIL-2Rα (× 103) . | sIL-2Rα (× 103) . | β2M . | sIL-2Rα (× 103) . | β2M . | sIL-2Rα (× 103) . | β2M . | |
| Control | 4.05 ± 2.98 | 35.89 ± 17.69 | 1.07 ± 0.65 | 526.3 ± 446.4 | 7.74 ± 3.33 | NA | NA |
| HAT | 4.04 ± 2.92 | 4.76 ± 8.78 | 0.11 ± 0.27 | 4.8 ± 6.2** | 0.63 ± 0.87*** | 100.9 ± 111.8 | 2.51 ± 2.54 |
| PRIT | 4.03 ± 3.46 | 1.89 ± 3.38 | 0.03 ± 0.08 | 9.8 ± 16.6** | 0.44 ± 0.84*** | 44.4 ± 62.6 | 1.33 ± 2.25 |
| PRIT (ns) | 4.02 ± 3.16 | 17.14 ± 9.85 | 0.60 ± 0.38 | 259.0 ± 258.9 | 4.47 ± 2.87* | 359.6 ± 123.5 | 8.43 ± 2.27 |
sIL-2Rα, soluble interleukin 2 receptor α; β2M, β-2-microglobulin; HAT, humanized anti-Tac; PRIT, pretargeting radioimmunotherapy; ns, nonspecific.
Units are picogram per milliliter for sIL-2Rα and microgram per milliliter for β2M. Control group did not receive any treatment. HAT group received HAT antibody 100 μg per week for 4 weeks. PRIT group received 140 μg HAT-SA pretargeting for 24 hours, 100 μg sCA for 4 hours, and 0.3 μg DOTA-biotin labeled with 250 μCi (9.25 MBq)213Bi. PRIT (ns) group received 140 μg B3-SA pretargeting for 24 hours, 100 μg sCA for 4 hours, and 0.3 μg DOTA-biotin labeled with 250 μCi (9.25 MBq) 213Bi. NA, not available (no mice surviving). *P < .05, **P < .005, ***P < .0005 compared with control group.